Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Biotechnology

Iovance Biotherapeutics, Inc. operates as a biotechnology company. The Company focuses on the development and commercialization of novel cancer immunotherapies based on tumor infiltrating lymphocytes for treatment of patients with cancer. Iovance Biotherapeutics serves customers in the United States.
Website: iovance.com



Growth: Bad revenue growth rate 0.0%, are preserved at an average historical level 0.0%. The revenue growth dynamics is unstable

Profitability: LTM EBITDA margin is negative, 0.0%. In the last quarter the company beat the estimated EPS. The company was ahead of estimated EPS in 80% of quarters (showing a gain of +$0.06 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield -25.0% (LTM)

Entry Point: Share price is 88.6% higher than minimum and 82.1% lower than maximum for the last 3 years

Insiders: For the last 3 months insiders bought company shares on $0.1 mln (0.039% of cap.)

Key Financials (Download financials)

Ticker: IOVA
Share price, USD:  (-4.9%)3.13
year average price 6.21  


year start price 9.25 2024-07-27

max close price 12.28 2024-11-07

min close price 1.66 2025-05-16

current price 3.13 2025-07-26
Common stocks: 157 168 000

Dividend Yield:  0.0%
EV / Sales: 200.0x
Margin (EBITDA LTM / Revenue):
Fundamental value created in LTM:
Market Cap ($m): 492
Net Debt ($m): -30
EV (Enterprise Value): 462
Price to Book: 0.6x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2025-07-18globenewswire.com

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

2025-07-18seekingalpha.com

Iovance: I'm Switching From Sell To Buy Despite Likely Approval For Rival Drug

2025-07-15globenewswire.com

IOVANCE INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Iovance Biotherapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

2025-07-14businesswire.com

FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Iovance Biotherapeutics

2025-07-14prnewswire.com

IOVA Shareholders Have the Right to Lead the Iovance Biotherapeutics, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - ELV

2025-07-14prnewswire.com

IOVA Investors Have Opportunity to Lead Iovance Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

2025-07-13globenewswire.com

IOVA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Iovance Biotherapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

2025-07-13prnewswire.com

IOVA Deadline: IOVA Investors with Losses in Excess of $100K Have Opportunity to Lead Iovance Biotherapeutics, Inc. Securities Fraud Lawsuit

2025-07-12globenewswire.com

IOVANCE DEADLINE ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Iovance Biotherapeutics, Inc. and Urgently Encourages Investors to Contact the Firm

2025-07-12globenewswire.com

IOVA FINAL DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Iovance Biotherapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important July 14 Deadline in Securities Class Action – IOVA
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol IOVA IOVA IOVA IOVA IOVA IOVA IOVA IOVA IOVA
reportedCurrency USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2024-11-07 2024-08-08 2024-05-09 2024-02-28 2023-11-07 2023-08-08 2023-05-10 2023-02-28 2022-11-03
acceptedDate 2024-11-07 17:15:37 2024-08-08 17:10:32 2024-05-09 17:10:44 2024-02-28 17:15:45 2023-11-07 17:15:48 2023-08-08 17:15:40 2023-05-10 16:30:58 2023-02-28 17:15:47 2022-11-03 17:16:37
calendarYear 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
revenue 59M 31M 715 000 482 000 469 000 238 000 0 0 0
costOfRevenue 40M 37M 13M 14M 4M 2M 0 0 0
grossProfit 19M -6M -12M -14M -4M -2M 0 0 0
grossProfitRatio 0.32 -0.181 -16.531 -28.21 -8.254 -7.613 0 0 0
researchAndDevelopmentExpenses 68M 62M 80M 87M 88M 86M 83M 81M 73M
generalAndAdministrativeExpenses 0 0 8M 49M 27M 22M 28M 26M 28M
sellingAndMarketingExpenses 0 0 18M -29M 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 40M 34M 26M 20M 27M 22M 28M 26M 28M
otherExpenses -1000 0 0 6M 0 0 0 0 0
operatingExpenses 108M 96M 106M 108M 114M 108M 111M 107M 100M
costAndExpenses 148M 133M 118M 122M 119M 110M 111M 107M 100M
interestIncome 4M 3M 3M 3M 3M 3M 3M 2M 777 000
interestExpense 0 0 0 3M 0 0 -3M 2M 777 000
depreciationAndAmortization 0 11M 10M 10M 10M 8M 6M 6M 0
ebitda -89M -91M -108M -112M -118M -110M -111M -107M -100M
ebitdaratio -1.521 -2.927 -150.79 -231.415 -252.369 -462.546 0 0 0
operatingIncome -89M -102M -118M -121M -118M -110M -111M -107M -100M
operatingIncomeRatio -1.521 -3.276 -164.646 -251.568 -252.369 -462.546 0 0 0
totalOtherIncomeExpensesNet 4M 3M 3M 3M 3M 3M 3M 2M 777 000
incomeBeforeTax -85M -99M -114M -118M -115M -107M -107M -105M -100M
incomeBeforeTaxRatio -1.453 -3.168 -159.978 -245.1 -245.209 -449.601 0 0 0
incomeTaxExpense -2M -1M -1M -2M -1M -477 000 -3M -3M -777 000
netIncome -84M -97M -113M -116M -114M -107M -104M -102M -99M
netIncomeRatio -1.427 -3.122 -158.008 -241.45 -242.559 -447.597 0 0 0
eps -0.28 -0.34 -0.42 -0.45 -0.46 -0.47 -0.49 -0.62 -0.63
epsdiluted -0.28 -0.34 -0.42 -0.45 -0.46 -0.47 -0.49 -0.62 -0.63
weightedAverageShsOut 303M 285M 266M 256M 246M 224M 214M 165M 158M
weightedAverageShsOutDil 303M 285M 266M 256M 246M 224M 214M 165M 158M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link

Balance Sheet Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol IOVA IOVA IOVA IOVA IOVA IOVA IOVA IOVA IOVA
reportedCurrency USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2024-11-07 2024-08-08 2024-05-09 2024-02-28 2023-11-07 2023-08-08 2023-05-10 2023-02-28 2022-11-03
acceptedDate 2024-11-07 17:15:37 2024-08-08 17:10:32 2024-05-09 17:10:44 2024-02-28 17:15:45 2023-11-07 17:15:48 2023-08-08 17:15:40 2023-05-10 16:30:58 2023-02-28 17:15:47 2022-11-03 17:16:37
calendarYear 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
cashAndCashEquivalents 164M 229M 134M 115M 268M 230M 543M 232M 118M
shortTermInvestments 233M 184M 222M 165M 94M 21M 83M 240M 242M
cashAndShortTermInvestments 397M 413M 356M 280M 361M 251M 626M 472M 360M
netReceivables 56M 32M 234 000 151 000 1 33 000 0 0 0
inventory 39M 28M 18M 10M 9M 10M 0 0 0
otherCurrentAssets 7M 10M 11M 17M 12M 14M 11M 7M 10M
totalCurrentAssets 499M 482M 386M 308M 383M 275M 638M 472M 370M
propertyPlantEquipmentNet 179M 180M 183M 177M 179M 180M 180M 178M 169M
goodwill 0 0 0 0 0 0 0 0 0
intangibleAssets 307M 295M 294M 229M 224M 236M 0 0 0
goodwillAndIntangibleAssets 307M 295M 294M 229M 224M 236M 0 0 0
longTermInvestments 0 6M 6M 66M 66M 66M 0 0 0
taxAssets 0 0 0 0 -66M -66M 0 0 0
otherNonCurrentAssets 7M 327 000 259 000 270 000 67M 67M 7M -172M 7M
totalNonCurrentAssets 493M 482M 484M 473M 470M 482M 187M 6M 176M
otherAssets 0 0 0 0 0 0 0 186M 0
totalAssets 991M 964M 870M 780M 852M 757M 825M 664M 546M
accountPayables 32M 20M 26M 33M 19M 31M 32M 27M 24M
shortTermDebt 0 23M 11M 8M 10M 11M 13M 13M 7M
taxPayables 0 0 0 0 0 0 0 0 0
deferredRevenue 0 0 0 1 0 0 0 0 0
otherCurrentLiabilities 86M 50M 46M 69M 61M 47M 43M 52M 48M
totalCurrentLiabilities 118M 94M 83M 110M 91M 89M 87M 91M 79M
longTermDebt 67M 70M 1 000 000 1 000 000 68M 70M 70M 84M 73M
deferredRevenueNonCurrent 0 68M 71M 0 0 -1 000 000 0 0 0
deferredTaxLiabilitiesNonCurrent 32M 32M 33M 17M 18M 20M 0 0 0
otherNonCurrentLiabilities 0 0 1 000 000 67M 1 000 000 1 000 000 1 000 000 0 42M
totalNonCurrentLiabilities 100M 102M 107M 85M 87M 90M 71M 84M 73M
otherLiabilities 0 0 0 0 0 0 0 -12M 0
capitalLeaseObligations 66M 81M 72M 67M 78M 80M 82M 84M 79M
totalLiabilities 218M 196M 190M 196M 178M 179M 158M 164M 152M
preferredStock 3000 3000 3000 3000 3000 3000 3000 3000 3000
commonStock 13 000 12 000 12 000 11 000 11 000 9000 9000 8000 7000
retainedEarnings -2 306M -2 222M -2 125M -2 012M -1 896M -1 782M -1 676M -1 568M -1 463M
accumulatedOtherComprehensiveIncomeLoss 16M 526 000 116 000 3M -9M 325 000 -126 000 -902 000 -2M
othertotalStockholdersEquity 3 063M 2 990M 2 805M 2 594M 2 579M 2 360M 2 343M 2 069M 1 859M
totalStockholdersEquity 773M 769M 680M 585M 674M 579M 667M 500M 394M
totalEquity 773M 769M 680M 585M 674M 579M 667M 500M 394M
totalLiabilitiesAndStockholdersEquity 991M 964M 870M 780M 852M 757M 825M 664M 546M
minorityInterest 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 991M 964M 870M 780M 852M 757M 825M 664M 546M
totalInvestments 233M 190M 228M 231M 94M 21M 83M 240M 242M
totalDebt 79M 82M 84M 76M 78M 81M 82M 84M 80M
netDebt -85M -147M -50M -39M -189M -149M -461M -147M -38M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link

Cash Flow Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol IOVA IOVA IOVA IOVA IOVA IOVA IOVA IOVA IOVA
reportedCurrency USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2024-11-07 2024-08-08 2024-05-09 2024-02-28 2023-11-07 2023-08-08 2023-05-10 2023-02-28 2022-11-03
acceptedDate 2024-11-07 17:15:37 2024-08-08 17:10:32 2024-05-09 17:10:44 2024-02-28 17:15:45 2023-11-07 17:15:48 2023-08-08 17:15:40 2023-05-10 16:30:58 2023-02-28 17:15:47 2022-11-03 17:16:37
calendarYear 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
netIncome -84M -97M -113M -116M -114M -107M -107M -105M -100M
depreciationAndAmortization 2M 11M 10M 10M 10M 8M 6M 6M 5M
deferredIncomeTax -2M -1M -1M -2M -1M -477 000 0 0 0
stockBasedCompensation 31M 30M 17M 14M 16M 17M 16M 20M 20M
changeInWorkingCapital 71M -39M -33M 12M 6M -11M -13M 3M 11M
accountsReceivables -24M -31M -83 000 -149 000 33 000 -33 000 0 0 0
inventory -11M -9M -7M -923 000 354 000 -10M 0 0 0
accountsPayables 14M -10M -6M 11M -10M 146 000 3M 2M 4M
otherWorkingCapital 92M 12M -20M 2M 15M -2M -3M 1M 7M
otherNonCashItems -78M 100M 47M -2M -666 000 -58 000 -978 000 -571 000 133 000
netCashProvidedByOperatingActivities -59M -98M -122M -84M -84M -94M -100M -78M -64M
investmentsInPropertyPlantAndEquipment -2M -442 000 -4M -4M -4M -10M -6M -3M -1M
acquisitionsNet 0 0 -53M 253 000 -3M -210M 0 0 0
purchasesOfInvestments -157M -74M -142M -108M -93M 210M -5M -96M -64M
salesMaturitiesOfInvestments 110M 115M 87M 38M 21M 62M 164M 99M 139M
otherInvestingActivites 0 41M -55M -70M -72M -210M 0 0 0
netCashUsedForInvestingActivites -49M 40M -112M -73M -79M -157M 153M 461 000 74M
debtRepayment 0 0 0 0 0 0 0 0 0
commonStockIssued 48M 152M 198M 1M 203M 1M 260M 190M 0
commonStockRepurchased 0 0 -5M -186 000 -379 000 -301 000 0 2M 0
dividendsPaid 0 0 0 0 0 0 0 0 0
otherFinancingActivites -6M 952 000 -5M -186 000 -379 000 0 -2M -582 000 225 000
netCashUsedProvidedByFinancingActivities 42M 153M 194M 962 000 203M 1M 258M 191M 225 000
effectOfForexChangesOnCash 1M -125 000 -491 000 3M -2M -4M 0 0 0
netChangeInCash -65M 95M 19M -153M 38M -253M 312M 113M 10M
cashAtEndOfPeriod 171M 229M 134M 115M 268M 296M 550M 238M 125M
cashAtBeginningOfPeriod 229M 134M 115M 268M 230M 550M 238M 125M 115M
operatingCashFlow -59M -98M -122M -84M -84M -94M -100M -78M -64M
capitalExpenditure -2M -442 000 -4M -4M -4M -10M -6M -3M -1M
freeCashFlow -61M -99M -126M -87M -88M -103M -105M -81M -65M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link

Earning call transcript

2024 q3
2024-11-07 ET (fiscal 2024 q3)
2024 q2
2024-08-08 ET (fiscal 2024 q2)
2024 q1
2024-05-09 ET (fiscal 2024 q1)
2023 q4
2024-02-28 ET (fiscal 2023 q4)
2023 q3
2023-11-07 ET (fiscal 2023 q3)
2023 q2
2023-08-08 ET (fiscal 2023 q2)
2023 q1
2023-05-09 ET (fiscal 2023 q1)
2022 q4
2023-03-01 ET (fiscal 2022 q4)
2022 q3
2022-11-03 ET (fiscal 2022 q3)
2022 q2
2022-08-04 ET (fiscal 2022 q2)
2022 q1
2022-05-05 ET (fiscal 2022 q1)

Press-releases

Show financial reports only

2024-10-31 20:01 ET
Iovance Biotherapeutics to Host Third Quarter and Year-to-Date 2024 Financial Results Conference Call and Webcast on Thursday, November 7, 2024
2024-09-03 21:00 ET
Iovance Biotherapeutics to Present at Upcoming Conferences
2024-08-08 20:01 ET
Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Second Quarter and First Half 2024
2024-07-29 20:01 ET
Iovance Biotherapeutics to Host Second Quarter and First Half 2024 Financial Results Conference Call and Webcast on Thursday, August 8, 2024
2024-06-28 11:00 ET
Iovance Biotherapeutics Submits Marketing Authorization Application to European Medicines Agency for Lifileucel in Advanced Melanoma
2024-06-21 21:00 ET
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
2024-05-24 20:01 ET
Iovance Biotherapeutics to Present at Upcoming Conferences and Events
2024-05-23 21:00 ET
Iovance Biotherapeutics Announces Clinical Data in Frontline Advanced Melanoma at ASCO 2024 Annual Meeting
2024-05-17 21:15 ET
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
2024-05-09 20:01 ET
Iovance Biotherapeutics Reports First Quarter 2024 Financial Results and Corporate Updates
2024-05-01 10:01 ET
Iovance Biotherapeutics to Host First Quarter 2024 Financial Results Conference Call and Webcast on Thursday, May 9, 2024
2024-04-30 10:01 ET
Iovance Biotherapeutics to Present at Upcoming Conferences
2024-04-24 20:01 ET
Iovance Biotherapeutics to Present Clinical and Translational Data at 2024 ASCO Annual Meeting
2024-04-19 21:15 ET
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
2024-03-22 21:30 ET
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
2024-03-04 11:30 ET
Iovance Biotherapeutics Announces FDA has Lifted Clinical Hold on the IOV-LUN-202 Registrational Trial in Non-Small Cell Lung Cancer
2024-03-01 22:00 ET
Iovance Biotherapeutics to Present at Upcoming Conferences
2024-02-28 21:01 ET
Iovance Biotherapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates 
2024-02-22 13:45 ET
Iovance Biotherapeutics to Host Fourth Quarter and Full-Year 2023 Financial Results Conference Call and Webcast on Wednesday, February 28, 2024
2024-02-20 13:00 ET
WuXi Advanced Therapies Receives FDA Approval to Manufacture Iovance's AMTAGVI™ (lifileucel) for Advanced Melanoma
2024-02-20 11:30 ET
Iovance Biotherapeutics, Inc. Announces Pricing of $211 Million Underwritten Offering of Common Stock
2024-02-20 11:30 ET
Iovance Biotherapeutics, Inc. Announces Pricing of $211 Million Underwritten Offering of Common Stock
2024-02-16 22:30 ET
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
2024-02-16 20:38 ET
Iovance Biotherapeutics to Host Conference Call and Webcast on Friday, February 16, 2024
2024-02-16 20:19 ET
Iovance’s AMTAGVI™ (lifileucel) Receives U.S. FDA Accelerated Approval for Advanced Melanoma
2024-01-19 22:15 ET
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
2023-12-27 12:00 ET
Iovance Biotherapeutics Announces Clinical Program Update for LN-145 in Non-Small Cell Lung Cancer
2023-12-22 22:15 ET
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
2023-11-17 22:00 ET
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
2023-11-07 21:01 ET
Iovance Biotherapeutics Reports Third Quarter and Year-to-Date 2023 Financial Results and Corporate Updates
2023-10-31 20:01 ET
Iovance Biotherapeutics to Host Third Quarter and Year-to-Date 2023 Financial Results Conference Call and Webcast on Tuesday, November 7, 2023
2023-10-31 13:05 ET
Iovance Biotherapeutics to Present Clinical and Pre-Clinical Data for Tumor Infiltrating Lymphocyte (TIL) Therapies at Society for Tumor Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
2023-10-20 21:15 ET
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
2023-10-16 12:15 ET
Iovance Biotherapeutics Announces Clinical Data for Lifileucel in Advanced Mucosal Melanoma at the European Society for Medical Oncology (ESMO) Congress
2023-09-27 20:01 ET
Iovance Biotherapeutics to Present Clinical and Pre-Clinical Data for Tumor Infiltrating Lymphocyte (TIL) Therapies at Society for Tumor Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
2023-09-22 22:25 ET
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
2023-09-14 22:10 ET
U.S. Food and Drug Administration Updates Prescription Drug User Fee Act (PDUFA) Action Date for Lifileucel for the Treatment of Advanced Melanoma
2023-09-07 11:31 ET
Iovance Biotherapeutics to Present at 2023 Wells Fargo Healthcare Conference
2023-08-18 21:00 ET
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
2023-08-08 20:01 ET
Iovance Biotherapeutics Reports Second Quarter and First Half 2023 Financial Results and Corporate Updates
2023-07-25 20:01 ET
Iovance Biotherapeutics to Present Clinical Data for Tumor Infiltrating Lymphocyte (TIL) Therapy at IASLC 2023 World Conference on Lung Cancer
2023-07-24 20:01 ET
Iovance Biotherapeutics to Host Second Quarter 2023 Financial Results Conference Call and Webcast on Tuesday, August 8, 2023
2023-07-21 21:34 ET
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
2023-07-13 20:01 ET
Iovance Biotherapeutics Announces Closing of $172.5 Million Common Stock Public Offering
2023-07-11 01:46 ET
Iovance Biotherapeutics, Inc. Announces Pricing of Its Public Offering of $150 Million of Common Stock
2023-07-10 20:34 ET
Iovance Biotherapeutics, Inc. Announces Proposed Public Offering of Common Stock
2023-07-10 11:00 ET
Iovance Biotherapeutics Announces Regulatory and Clinical Updates for TIL Therapy in Advanced Non-Small Cell Lung Cancer
2023-06-20 11:01 ET
Iovance Biotherapeutics to Host Virtual Roundtable with Key Opinion Leaders to Discuss Melanoma Treatment Landscape
2023-06-15 11:01 ET
Iovance Biotherapeutics Announces First Patient Randomized in Phase 3 TILVANCE-301 Trial in Frontline Advanced Melanoma
2023-06-09 11:01 ET
Iovance Biotherapeutics to Present at Jefferies Global Healthcare Conference
2023-05-26 21:30 ET
Iovance Biotherapeutics Announces U.S. Food and Drug Administration Acceptance of the Biologics License Application of Lifileucel for the Treatment of Advanced Melanoma
2023-05-09 20:01 ET
Iovance Biotherapeutics Reports First Quarter 2023 Financial Results and Corporate Updates
2023-05-02 20:01 ET
Iovance Biotherapeutics to Host First Quarter 2023 Financial Results Conference Call and Webcast on Tuesday, May 9, 2023
2023-04-24 11:01 ET
Iovance Biotherapeutics to Present at Upcoming Conferences
2023-03-24 20:01 ET
Iovance Biotherapeutics Completes Biologics License Application (BLA) Submission for Lifileucel in Advanced Melanoma
2023-03-01 13:03 ET
Iovance Biotherapeutics to Present at Upcoming Conferences
2023-02-28 21:01 ET
Iovance Biotherapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Updates
2023-02-21 21:01 ET
Iovance Biotherapeutics to Host Fourth Quarter and Full Year 2022 Financial Results Conference Call and Webcast on Tuesday, February 28, 2023
2023-01-23 13:00 ET
Iovance Biotherapeutics Provides Corporate, Clinical, and Regulatory Updates
2022-11-30 12:00 ET
Iovance Biotherapeutics to Present at Upcoming Conferences
2022-11-18 11:30 ET
Iovance Biotherapeutics Provides Update on Biologics License Application Submission for Lifileucel in Advanced Melanoma
2022-11-10 17:33 ET
Iovance Biotherapeutics Announces Updated Clinical Data for Lifileucel in Advanced Melanoma at Society for Immunotherapy of Cancer (SITC) Annual Meeting
2022-11-07 13:01 ET
Iovance Biotherapeutics Announces Updated Clinical Data for Lifileucel in Advanced Melanoma at Society for Immunotherapy of Cancer (SITC) Annual Meeting
2022-11-03 20:01 ET
Iovance Biotherapeutics Reports Third Quarter and Year-to-Date 2022 Financial Results and Corporate Updates
2022-10-24 20:01 ET
Iovance Biotherapeutics to Host Third Quarter Financial Results Conference Call and Webcast on Thursday, November 3, 2022
2022-10-10 11:30 ET
Iovance Biotherapeutics Announces First Patient Dosed with PD-1 Inactivated Tumor Infiltrating Lymphocyte (TIL) Therapy
2022-10-05 12:05 ET
Iovance Biotherapeutics to Present Clinical Data for Lifileucel Tumor Infiltrating Lymphocyte (TIL) Therapy in Advanced Melanoma at Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting
2022-09-06 20:01 ET
Iovance Biotherapeutics to Present at Upcoming Conferences
2022-09-06 13:00 ET
Iovance Biotherapeutics to Present Posters at ESMO 2022
2022-08-25 11:30 ET
Iovance Biotherapeutics Initiates Biologics License Application (BLA) Submission for Lifileucel in Advanced Melanoma
2022-08-04 20:01 ET
Iovance Biotherapeutics Reports Second Quarter and First Half 2022 Financial Results and Corporate Updates
2022-07-27 11:00 ET
Iovance Biotherapeutics to Host Second Quarter Financial Results Conference Call and Webcast on Thursday, August 4, 2022
2022-07-22 21:15 ET
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
2022-06-17 21:15 ET
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
2022-06-13 20:01 ET
Iovance Biotherapeutics Appoints Wendy L. Dixon, Ph.D., to Board of Directors
2022-06-08 20:01 ET
Iovance Biotherapeutics to Present at Upcoming Conferences
2022-05-26 20:01 ET
Iovance Biotherapeutics Announces Positive Clinical Data for Lifileucel in Advanced Melanoma
2022-05-20 21:15 ET
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
2022-05-05 20:01 ET
Iovance Biotherapeutics Reports First Quarter 2022 Financial Results and Corporate Updates
2022-04-27 20:01 ET
Iovance Biotherapeutics to Present Translational Data for Lifileucel in Advanced Melanoma at 2022 ASCO Annual Meeting
2022-04-26 11:30 ET
Iovance Biotherapeutics to Host First Quarter Financial Results Conference Call and Webcast on Thursday, May 5, 2022
2022-04-25 20:01 ET
Iovance Biotherapeutics to Present at Chardan Genetic Medicines and Cell Therapy Manufacturing Summit
2022-04-22 21:15 ET
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
2022-04-05 20:05 ET
Iovance Biotherapeutics Announces Regulatory and Clinical Updates for Lifileucel in Melanoma
2022-03-16 11:01 ET
Iovance Biotherapeutics to Present at Upcoming Conferences
2022-03-15 21:15 ET
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
2022-03-08 21:31 ET
Iovance Biotherapeutics to Present at American Association for Cancer Research (AACR) 2022 Annual Meeting
2022-02-24 21:01 ET
Iovance Biotherapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Updates
2022-02-18 22:15 ET
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
2022-02-11 21:01 ET
Iovance Biotherapeutics to Host Fourth Quarter and Full Year Financial Results Conference Call and Webcast on Thursday, February 24, 2022
2022-01-21 22:15 ET
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
2022-01-10 13:00 ET
Iovance Biotherapeutics Announces Raj K. Puri, M.D., Ph.D. to Join Leadership Team
2022-01-07 21:01 ET
Iovance Biotherapeutics to Present Data on Tumor-Infiltrating Lymphocyte (TIL) Cell Therapy at the 2022 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT™ and CIBMTR®
2022-01-06 22:38 ET
Iovance Biotherapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference on January 12, 2022
2021-12-17 22:15 ET
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
2021-12-07 13:40 ET
Iovance Biotherapeutics to Present at Upcoming Conferences
2021-11-19 22:15 ET
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
2021-11-13 21:30 ET
Iovance Biotherapeutics Announces Clinical Data for Lifileucel in Combination with Pembrolizumab in Advanced Cancers at Society for Immunotherapy of Cancer (SITC) Annual Meeting
2021-11-12 12:01 ET
Iovance Biotherapeutics Announces Clinical Data for LN-145 in Non-Small Cell Lung Cancer at Society for Immunotherapy of Cancer (SITC) Annual Meeting
2021-11-09 13:54 ET
Iovance Biotherapeutics Announces Clinical Data for Tumor Infiltrating Lymphocyte (TIL) Cell Therapy in Multiple Solid Tumors at Society for Immunotherapy of Cancer (SITC) Annual Meeting
2021-11-08 21:01 ET
Iovance Biotherapeutics to Present at Upcoming Conferences
2021-11-04 20:01 ET
Iovance Biotherapeutics Reports Third Quarter and Year-to-Date 2021 Financial Results and Corporate Updates
2021-10-25 20:01 ET
Iovance Biotherapeutics to Host Third Quarter Financial Results Conference Call and Webcast on Thursday, November 4, 2021
2021-10-18 20:01 ET
Iovance Biotherapeutics to Host Conference Call and Webcast to Highlight Data at Society for Immunotherapy of Cancer (SITC) Annual Meeting
2021-10-01 12:47 ET
Iovance Biotherapeutics to Present Clinical Data for Tumor Infiltrating Lymphocyte (TIL) Cell Therapies Across Multiple Solid Tumors and Treatment Settings at the Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting
2021-09-28 21:00 ET
Iovance Biotherapeutics Celebrates Grand Opening of Iovance Cell Therapy Center (iCTC) in the Philadelphia Navy Yard
2021-09-23 11:30 ET
Iovance Biotherapeutics Initiates Clinical Supply of Tumor-Infiltrating Lymphocyte (TIL) Cell Therapy Manufactured at Iovance Cell Therapy Center (iCTC)
2021-08-05 20:01 ET
Iovance Biotherapeutics Reports Second Quarter and First Half 2021 Financial Results and Corporate Updates
2021-07-19 20:30 ET
Iovance Biotherapeutics to Host Second Quarter Financial Results Conference Call and Webcast on Thursday, August 5, 2021
2021-06-29 19:38 ET
Iovance Biotherapeutics to Host Conference Call and Webcast to Discuss Clinical Data for LN-145 in Non-Small Cell Lung Cancer on June 29, 2021 at 4:30pm ET
2021-06-29 10:30 ET
Iovance Biotherapeutics Announces Clinical Data for LN-145 in Non-Small Cell Lung Cancer
2021-06-06 13:24 ET
Iovance Biotherapeutics Announces 33-Month Follow Up Data for Lifileucel in Advanced Melanoma at ASCO 2021 Annual Meeting
2021-06-04 13:08 ET
Iovance Biotherapeutics Announces Clinical Data for Lifileucel in Combination with Pembrolizumab in Advanced Melanoma at ASCO 2021 Annual Meeting
2021-06-01 11:30 ET
Iovance Biotherapeutics to Present at Upcoming Conferences
2021-05-19 21:04 ET
Iovance Biotherapeutics Announces Clinical Data Updates for Lifileucel in Advanced Melanoma at Upcoming ASCO 2021 Annual Meeting
2021-05-18 20:30 ET
Iovance Biotherapeutics Provides Regulatory Update for Lifileucel Potency Assays
2021-05-12 20:35 ET
Journal of Clinical Oncology Publishes Clinical Data for Cohort 2 in Iovance C-144-01 Study of Lifileucel TIL Therapy in Metastatic Melanoma
2021-05-06 20:01 ET
Iovance Biotherapeutics Reports First Quarter 2021 Financial Results and Corporate Updates
2021-05-04 20:30 ET
Iovance Biotherapeutics to Present at Upcoming Conferences
2021-04-28 14:50 ET
Iovance Biotherapeutics to Present Clinical Data for Lifileucel in Advanced Melanoma at ASCO 2021 Annual Meeting
2021-04-27 20:01 ET
Iovance Biotherapeutics to Host First Quarter Financial Results Conference Call and Webcast on Thursday, May 6, 2021
2021-04-09 11:00 ET
Iovance Biotherapeutics Announces Clinical Data Updates for Lifileucel in Advanced Melanoma During American Association for Cancer Research (AACR) 2021 Annual Meeting
2021-03-15 20:01 ET
Iovance Biotherapeutics Appoints Igor Bilinsky as Chief Operating Officer
2021-03-10 22:28 ET
Iovance Biotherapeutics to Present Updated Clinical Data for Tumor Infiltrating Lymphocyte (TIL) Therapy Lifileucel in Advanced Melanoma at American Association for Cancer Research (AACR) 2021 Annual Meeting
2021-03-01 21:01 ET
Iovance Biotherapeutics to Present at Upcoming Healthcare Conferences
2021-02-25 21:01 ET
Iovance Biotherapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Corporate Updates
2021-02-18 12:30 ET
Iovance Biotherapeutics to Host Fourth Quarter and Full Year 2020 Financial Results Conference Call and Webcast on Thursday, February 25, 2021
2021-01-19 13:56 ET
Iovance Biotherapeutics to Present at Upcoming Healthcare Conferences
2020-12-28 12:30 ET
Iovance Biotherapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference on January 14, 2021
2020-12-14 12:00 ET
Iovance Biotherapeutics Appoints Jean-Marc Bellemin as Chief Financial Officer
2020-11-30 12:21 ET
Iovance Biotherapeutics to Present at Upcoming Conferences in December
2020-11-09 13:00 ET
Iovance Biotherapeutics Presents Clinical Data in Head and Neck Cancer at Society for Immunotherapy of Cancer (SITC) 35th Annual Meeting
2020-11-05 21:00 ET
Iovance Biotherapeutics Reports Third Quarter and Year-to-Date 2020 Financial Results and Corporate Updates
2020-10-30 11:00 ET
Iovance Biotherapeutics to Host Third Quarter 2020 Financial Results Conference Call and Webcast on Thursday, November 5, 2020
2020-10-28 11:45 ET
Iovance Biotherapeutics to Present at Upcoming Conferences in November
2020-10-14 21:01 ET
Iovance Biotherapeutics to Present Clinical Data in Head and Neck Cancer at Society for Immunotherapy of Cancer (SITC) 35th Annual Meeting
2020-10-06 11:00 ET
Iovance Biotherapeutics to Present at Upcoming October Conferences
2020-10-05 20:01 ET
Iovance Biotherapeutics Provides Update for Lifileucel in Metastatic Melanoma
2020-08-07 11:30 ET
Iovance Biotherapeutics to Present at BTIG Biotechnology Conference 2020
2020-08-06 20:01 ET
Iovance Biotherapeutics Reports Second Quarter 2020 Financial Results and Provides a Corporate Update
2020-08-06 12:05 ET
Avid Bioservices Selected By Iovance Biotherapeutics to Lead Process Development Through CGMP Manufacturing of Novel IL-2 Analog, IOV-3001
2020-07-23 11:30 ET
Iovance Biotherapeutics to Host Second Quarter 2020 Financial Results Conference Call and Webcast on Thursday, August 6, 2020
2020-06-08 20:01 ET
Iovance Biotherapeutics to Present at Upcoming June Conferences
2020-06-02 20:01 ET
Iovance Biotherapeutics, Inc. Announces Closing of $603.7 Million Common Stock Public Offering
2020-05-29 12:01 ET
Iovance Presents Updated Clinical Data for Tumor Infiltrating Lymphocyte (TIL) Therapy Lifileucel in Advanced Melanoma at ASCO Scientific Program
2020-05-29 01:30 ET
Iovance Biotherapeutics, Inc. Announces Pricing of Its Public Offering of Approximately $525 Million of Common Stock
2020-05-27 20:20 ET
Iovance Biotherapeutics, Inc. Announces Proposed Public Offering of Common Stock
2020-05-27 20:01 ET
Iovance Reports Pivotal Cohort 4 Data for Tumor Infiltrating Lymphocyte (TIL) Therapy Lifileucel from C-144-01 Clinical Study in Advanced Melanoma
2020-05-13 21:01 ET
Iovance Biotherapeutics Announces Clinical Data Updates for Lifileucel in Advanced Melanoma
2020-05-05 20:01 ET
Iovance Biotherapeutics Reports First Quarter 2020 Financial Results and Provides a Corporate Update
2020-04-29 16:01 ET
Iovance Biotherapeutics to Present Updated Data from Clinical Study in Advanced Melanoma at ASCO 2020 Virtual Scientific Program
2020-04-27 20:01 ET
Iovance Biotherapeutics to Host First Quarter 2020 Financial Results Conference Call and Webcast on Tuesday, May 5, 2020
2020-04-13 21:14 ET
Iovance Biotherapeutics Announces H. Lee Moffitt Cancer Center to Present Lung Cancer Clinical Data at American Association for Cancer Research (AACR) Virtual Annual Meeting 2020
2020-03-02 21:01 ET
Iovance Biotherapeutics to Present at Upcoming Conferences
2020-02-25 21:01 ET
Iovance Biotherapeutics Reports Fourth Quarter and Full-Year 2019 Financial Results and Provides Corporate Update
2020-02-19 12:00 ET
Iovance Biotherapeutics to Host Fourth Quarter and Full Year 2019 Financial Results Conference Call and Webcast on Tuesday, February 25, 2020
2020-02-12 12:00 ET
Iovance Biotherapeutics to Present at Upcoming Healthcare Conferences
2020-01-15 13:00 ET
Iovance Biotherapeutics Completes Patient Dosing in Registration-Enabling Cohort 4 of the C-144-01 Melanoma Study with Lifileucel
2020-01-12 21:30 ET
Iovance Biotherapeutics Obtains License to Develop and Commercialize a Novel IL-2 Analog
2020-01-12 21:00 ET
Iovance Biotherapeutics and Cellectis Enter into a Research Collaboration and Exclusive Worldwide License Agreement
2019-12-02 12:00 ET
Iovance Biotherapeutics to Present at Upcoming Investor Conferences in December
2019-11-21 12:00 ET
Iovance Biotherapeutics Announces Results of a Subgroup Analysis of Patients in the Lifileucel Metastatic Melanoma Study who are Primary Refractory to Anti-PD-1/L1 Therapy
2019-11-08 12:00 ET
Iovance Biotherapeutics Announces Updated Phase 2 Clinical Data from the Lifileucel Metastatic Melanoma Trial at the Society for Immunotherapy of Cancer 34th Annual Meeting
2019-11-07 21:32 ET
Iovance Biotherapeutics to Present at Upcoming Investor Conferences in November
2019-11-04 21:01 ET
Iovance Biotherapeutics Reports Third Quarter and September Year-to-Date 2019 Financial Results
2019-10-31 20:43 ET
Iovance Biotherapeutics to Host Third Quarter 2019 Financial Results Conference Call and Webcast on Monday, November 4, 2019
2019-10-02 11:00 ET
Iovance Biotherapeutics Announces Four Abstracts to be Presented at the Upcoming 2019 SITC Annual Meeting
2019-09-27 20:30 ET
Iovance Biotherapeutics to Present at Upcoming Conferences
2019-05-17 13:31 ET
Thinking about buying stock in Aurora Cannabis, Applied Materials, Iovance Biotherapeutics, NVIDIA, or Under Armour?

SEC forms

Show financial reports only

SEC form 10
2025-05-08 21:15 ET
Iovance Biotherapeutics reported for 2025 q1
SEC form 8
2025-05-08 20:05 ET
Iovance Biotherapeutics published news for 2025 q1
SEC form 8
2025-05-08 20:05 ET
Iovance Biotherapeutics published news for 2025 q1
SEC form 10
2025-05-08 00:00 ET
Iovance Biotherapeutics reported for 2025 q1
SEC form 10
2025-02-27 17:15 ET
Iovance Biotherapeutics reported for 2024 q4
SEC form 8
2025-02-27 16:05 ET
Iovance Biotherapeutics published news for 2024 q4
SEC form 8
2025-02-27 16:05 ET
Iovance Biotherapeutics reported for 2024 q4
SEC form 10
2025-02-27 00:00 ET
Iovance Biotherapeutics reported for 2024 q4
SEC form 8
2025-02-10 12:22 ET
Iovance Biotherapeutics published news for 2024 q4
SEC form 8
2025-02-10 12:22 ET
Iovance Biotherapeutics published news for 2024 q4
SEC form 10
2024-11-07 17:15 ET
Iovance Biotherapeutics reported for 2024 q3
SEC form 8
2024-11-07 16:06 ET
Iovance Biotherapeutics published news for 2024 q3
SEC form 8
2024-11-07 16:06 ET
Iovance Biotherapeutics reported for 2024 q3
SEC form 10
2024-08-08 17:10 ET
Iovance Biotherapeutics reported for 2024 q2
SEC form 8
2024-08-08 16:05 ET
Iovance Biotherapeutics published news for 2024 q2
SEC form 8
2024-08-08 16:05 ET
Iovance Biotherapeutics published news for 2024 q2
SEC form 10
2024-08-08 00:00 ET
Iovance Biotherapeutics reported for 2024 q2
SEC form 10
2024-05-09 00:00 ET
Iovance Biotherapeutics reported for 2024 q1
SEC form 8
2024-05-09 00:00 ET
Iovance Biotherapeutics published news for 2024 q1
SEC form 8
2024-05-09 00:00 ET
Iovance Biotherapeutics published news for 2024 q1
SEC form 10
2024-02-28 17:15 ET
Iovance Biotherapeutics reported for 2023 q4
SEC form 8
2024-02-28 16:05 ET
Iovance Biotherapeutics published news for 2023 q4
SEC form 8
2024-02-28 16:05 ET
Iovance Biotherapeutics reported for 2023 q4
SEC form 10
2024-02-28 00:00 ET
Iovance Biotherapeutics reported for 2023 q4
SEC form 8
2024-02-20 00:00 ET
Iovance Biotherapeutics published news for 2023 q4
SEC form 8
2024-02-20 00:00 ET
Iovance Biotherapeutics published news for 2023 q4
SEC form 8
2024-02-20 00:00 ET
Iovance Biotherapeutics published news for 2023 q4
SEC form 10
2023-11-07 17:15 ET
Iovance Biotherapeutics reported for 2023 q3
SEC form 8
2023-11-07 16:05 ET
Iovance Biotherapeutics published news for 2023 q3
SEC form 10
2023-11-07 00:00 ET
Iovance Biotherapeutics reported for 2023 q3
SEC form 10
2023-08-08 17:15 ET
Iovance Biotherapeutics reported for 2023 q2
SEC form 6
2023-08-08 16:05 ET
Iovance Biotherapeutics reported for 2023 q2
SEC form 10
2023-08-08 00:00 ET
Iovance Biotherapeutics reported for 2023 q2
SEC form 8
2023-08-08 00:00 ET
Iovance Biotherapeutics reported for 2023 q2
SEC form 6
2023-07-13 16:31 ET
Iovance Biotherapeutics published news for 2023 q2
SEC form 6
2023-07-11 16:55 ET
Iovance Biotherapeutics published news for 2023 q2
SEC form 6
2023-07-10 16:40 ET
Iovance Biotherapeutics published news for 2023 q2
SEC form 6
2023-07-10 08:53 ET
Iovance Biotherapeutics published news for 2023 q2
SEC form 8
2023-07-10 00:00 ET
Iovance Biotherapeutics published news for 2023 q2
SEC form 6
2023-06-16 16:51 ET
Iovance Biotherapeutics published news for 2023 q1
SEC form 10
2023-05-10 00:00 ET
Iovance Biotherapeutics reported for 2023 q1
SEC form 8
2023-05-09 00:00 ET
Iovance Biotherapeutics published news for 2023 q1
SEC form 6
2023-03-27 07:00 ET
Iovance Biotherapeutics published news for 2022 q4
SEC form 6
2023-03-10 16:44 ET
Iovance Biotherapeutics published news for 2022 q4
SEC form 10
2023-02-28 17:15 ET
Iovance Biotherapeutics reported for 2022 q4
SEC form 6
2023-02-28 16:05 ET
Iovance Biotherapeutics published news for 2022 q4
SEC form 10
2023-02-28 00:00 ET
Iovance Biotherapeutics reported for 2022 q4
SEC form 8
2023-02-28 00:00 ET
Iovance Biotherapeutics published news for 2022 q4
SEC form 6
2023-01-27 17:10 ET
Iovance Biotherapeutics published news for 2022 q4
SEC form 6
2023-01-23 08:14 ET
Iovance Biotherapeutics published news for 2022 q4
SEC form 6
2023-01-10 21:30 ET
Iovance Biotherapeutics published news for 2022 q4
SEC form 6
2022-11-18 17:19 ET
Iovance Biotherapeutics published news for 2022 q3
SEC form 6
2022-11-18 16:06 ET
Iovance Biotherapeutics published news for 2022 q3
SEC form 10
2022-11-03 17:16 ET
Iovance Biotherapeutics reported for 2022 q3
SEC form 6
2022-11-03 16:05 ET
Iovance Biotherapeutics reported for 2022 q3
SEC form 10
2022-11-03 00:00 ET
Iovance Biotherapeutics reported for 2022 q3
SEC form 8
2022-11-03 00:00 ET
Iovance Biotherapeutics reported for 2022 q3
SEC form 6
2022-09-12 17:00 ET
Iovance Biotherapeutics published news for 2022 q2
SEC form 6
2022-08-29 17:00 ET
Iovance Biotherapeutics published news for 2022 q2
SEC form 10
2022-08-04 16:46 ET
Iovance Biotherapeutics reported for 2022 q2
SEC form 6
2022-08-04 16:05 ET
Iovance Biotherapeutics reported for 2022 q2
SEC form 10
2022-08-04 00:00 ET
Iovance Biotherapeutics reported for 2022 q2
SEC form 8
2022-08-04 00:00 ET
Iovance Biotherapeutics reported for 2022 q2
SEC form 6
2022-06-13 17:15 ET
Iovance Biotherapeutics published news for 2022 q1
SEC form 6
2022-05-26 17:16 ET
Iovance Biotherapeutics published news for 2022 q1
SEC form 6
2022-05-13 17:16 ET
Iovance Biotherapeutics published news for 2022 q1
SEC form 10
2022-05-05 17:16 ET
Iovance Biotherapeutics reported for 2022 q1
SEC form 6
2022-05-05 16:05 ET
Iovance Biotherapeutics reported for 2022 q1
SEC form 10
2022-05-05 00:00 ET
Iovance Biotherapeutics reported for 2022 q1
SEC form 8
2022-05-05 00:00 ET
Iovance Biotherapeutics reported for 2022 q1
SEC form 6
2022-04-29 17:12 ET
Iovance Biotherapeutics published news for 2022 q1
SEC form 6
2022-04-27 17:02 ET
Iovance Biotherapeutics published news for 2022 q1
SEC form 6
2022-04-05 17:00 ET
Iovance Biotherapeutics published news for 2022 q1
SEC form 10
2022-02-24 17:14 ET
Iovance Biotherapeutics published news for 2021 q4
SEC form 6
2022-02-24 16:06 ET
Iovance Biotherapeutics published news for 2021 q4
SEC form 10
2022-02-24 00:00 ET
Iovance Biotherapeutics published news for 2021 q4
SEC form 8
2022-02-24 00:00 ET
Iovance Biotherapeutics published news for 2021 q4
SEC form 6
2022-01-19 17:15 ET
Iovance Biotherapeutics published news for 2021 q4
SEC form 6
2022-01-10 08:16 ET
Iovance Biotherapeutics published news for 2021 q4
SEC form 10
2021-11-04 17:15 ET
Iovance Biotherapeutics published news for 2021 q3
SEC form 6
2021-11-04 16:06 ET
Iovance Biotherapeutics published news for 2021 q3
SEC form 10
2021-11-04 00:00 ET
Iovance Biotherapeutics published news for 2021 q3
SEC form 8
2021-11-04 00:00 ET
Iovance Biotherapeutics published news for 2021 q3
SEC form 6
2021-09-23 16:49 ET
Iovance Biotherapeutics published news for 2021 q2
SEC form 10
2021-08-05 17:18 ET
Iovance Biotherapeutics published news for 2021 q2
SEC form 6
2021-08-05 16:05 ET
Iovance Biotherapeutics published news for 2021 q2
SEC form 10
2021-08-05 00:00 ET
Iovance Biotherapeutics published news for 2021 q2
SEC form 8
2021-08-05 00:00 ET
Iovance Biotherapeutics published news for 2021 q2
SEC form 6
2021-06-29 16:05 ET
Iovance Biotherapeutics published news for 2021 q1
SEC form 6
2021-06-14 17:13 ET
Iovance Biotherapeutics published news for 2021 q1
SEC form 6
2021-05-20 16:06 ET
Iovance Biotherapeutics published news for 2021 q1
SEC form 6
2021-05-19 11:47 ET
Iovance Biotherapeutics published news for 2021 q1
SEC form 10
2021-05-06 17:28 ET
Iovance Biotherapeutics published news for 2021 q1
SEC form 6
2021-05-06 16:06 ET
Iovance Biotherapeutics published news for 2021 q1
SEC form 10
2021-05-06 00:00 ET
Iovance Biotherapeutics published news for 2021 q1
SEC form 6
2021-04-27 17:20 ET
Iovance Biotherapeutics published news for 2021 q1
SEC form 6
2021-04-23 18:18 ET
Iovance Biotherapeutics published news for 2021 q1
SEC form 6
2021-04-12 16:10 ET
Iovance Biotherapeutics published news for 2021 q1
SEC form 6
2021-03-15 16:11 ET
Iovance Biotherapeutics published news for 2020 q4
SEC form 6
2021-03-12 17:15 ET
Iovance Biotherapeutics published news for 2020 q4
SEC form 6
2021-03-11 16:30 ET
Iovance Biotherapeutics published news for 2020 q4
SEC form 10
2021-02-25 17:15 ET
Iovance Biotherapeutics published news for 2020 q4
SEC form 6
2021-02-25 16:05 ET
Iovance Biotherapeutics published news for 2020 q4
SEC form 6
2021-02-09 06:01 ET
Iovance Biotherapeutics published news for 2020 q4
SEC form 6
2021-02-08 21:55 ET
Iovance Biotherapeutics published news for 2020 q4
SEC form 6
2021-01-07 06:05 ET
Iovance Biotherapeutics published news for 2020 q4
SEC form 6
2020-12-14 17:15 ET
Iovance Biotherapeutics published news for 2020 q3
SEC form 10
2020-11-05 17:16 ET
Iovance Biotherapeutics published news for 2020 q3
SEC form 6
2020-11-05 16:05 ET
Iovance Biotherapeutics published news for 2020 q3
SEC form 6
2020-10-14 17:06 ET
Iovance Biotherapeutics published news for 2020 q3
SEC form 6
2020-10-05 17:15 ET
Iovance Biotherapeutics published news for 2020 q3